research use only

Voreloxin (SNS-595) hydrochloride Topoisomerase inhibitor

Name: Voreloxin (SNS-595) hydrochloride
Brand: Selleck Chemicals
SKU: S7518
Availability: InStock
Rating: 5 (7 reviews)

Cat.No.S7518

Voreloxin hydrochloride (SNS-595, Vosaroxin) is a potent Topoisomerase II inhibitor with broad-spectrum anti-tumor activity. Phase 2.

Chemical Structure

Molecular Weight: 437.9

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: S751801 DMSO]20 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.99%

99.99

Related Targets	DNA/RNA Synthesis HDAC PPAR PARP Sirtuin ATM/ATR Casein Kinase eIF MDM2/MDMX DNA-PK DHFR Nucleoside Analog/Antimetabolite DNA alkylator Telomerase Thymidylate Synthase CRISPR/Cas9 RAD51 BMI-1 LIM kinase RNR Alkylating Agent NUDIX High-mobility Group OGG1 MTH1 G-quadruplex SMN FENs WRN Pax
Related Products	Camptothecin (CPT) (S)-10-Hydroxycamptothecin Beta-Lapachone Amonafide Ellagic acid Genz-644282 Hydroxy Camptothecine Rubitecan Eleutherin Clinafloxacin ABBV-969 Payload SW-044248 Cu(II)-Elesclomol Pefloxacin Mesylate Dihydrate Amsacrine hydrochloride Gepotidacin Topoisomerase IIα Antibody [H22C21] Cholesteryl hemisuccinate Dxd Ellipticine Betulinic acid Exatecan 7-Ethylcamptothecin 9-amino-CPT (9-Aminocamptothecin) Amsacrine Topoisomerase I Antibody [C12J2] Belotecan (CKD-602) hydrochloride Topoisomerase IIα Antibody [E2A15] Flumequine Merbarone

Chemical Information, Storage & Stability

Molecular Weight	437.9	Formula	C₁₈H₂₀ClN₅O₄S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	175519-16-1	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Vosaroxin			Smiles	CNC1CN(CC1OC)C2=NC3=C(C=C2)C(=O)C(=CN3C4=NC=CS4)C(=O)O.Cl

Solubility

In vitro
Batch:

DMSO : 20 mg/mL (45.67 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	Topo II ^[1]
In vitro	Voreloxin exhibits potent inhibitory effect in topoisomerase II relaxation with IC50 of 3.2 μg /mL without effect on topoisomerase II cleavage. Voreloxin has a cytotoxic activity against human tumor cell lines more potent than that of etoposide. ^[1] Voreloxin has broad anti-proliferative activity in 15 cell lines, including 4 drug-resistant lines, with IC50 ranging from 0.04 to 1.155 μM. ^[2]
In vivo	Voreloxin (50 mg/kg i.p.) shows potent in vivo antitumor activity mice implanted with P388 leukemia cells. ^[1] Voreloxin (25 mg/kg i.v.) demonstrates strong tumor growth inhibition in 10 of 11 solid tumor (breast, ovarian, colon, lung, gastric, and melanoma) xenograft models, 2 hematologic tumor xenograft models, 3 multidrug resistant tumor models and 3 murine syngeneic tumor models (Colon 26, Lewis Lung carcinoma, M5076 Ovarian Sarcoma). ^[2]
References	[1] https://pubmed.ncbi.nlm.nih.gov/15056007/ [2] https://pubmed.ncbi.nlm.nih.gov/18931998/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02658487	Active not recruiting	Acute Myeloid Leukemia\|Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome\|Acute Myeloid Leukemia With Multilineage Dysplasia\|Myeloid Sarcoma\|Secondary Acute Myeloid Leukemia\|Therapy-Related Acute Myeloid Leukemia\|Therapy-Related Myelodysplastic Syndrome	Vanderbilt-Ingram Cancer Center\|National Cancer Institute (NCI)	March 2016	Phase 2
NCT01913951	Completed	Myelodysplastic Syndromes	Washington University School of Medicine\|Sunesis Pharmaceuticals	November 22 2013	Phase 1
NCT01980056	Completed	Myelodysplastic Syndrome	Weill Medical College of Cornell University\|Sunesis Pharmaceuticals	October 25 2013	Phase 1\|Phase 2
NCT01893320	Completed	Leukemia	M.D. Anderson Cancer Center\|Sunesis Pharmaceuticals	July 18 2013	Phase 1\|Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):